Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States with a prevalence of 24% in adults (1) and 10%~20% in children (2) . NAFLD encompasses a spectrum of liver manifestations ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) (3) , which may progress to cirrhosis and hepatocellular carcinoma (4, 5) .
NAFLD is commonly referred to as the hepatic manifestation of the metabolic syndrome (6, 7), because of its association with risk factors such as central obesity, diabetes mellitus, and dyslipidemia (8, 9) . It is estimated that the prevalence of NAFLD among type 2 diabetics is as high as 69% (9) , and the estimated prevalence of diabetes among NAFLD and NASH patients is 22 .51% and 43.63%, respectively (1) , suggesting that NAFLD/ NASH and diabetes are highly associated.
NASH has been identified as a potential contributing factor to variable drug response (VDR). It has been demonstrated that NASH can alter the metabolism and disposition of many drugs, including ezetimibe, pravastatin, methotrexate, morphine, acetaminophen and metformin (10) (11) (12) (13) (14) (15) .
Remodeling of the hepatic absorption, distribution, metabolism, and excretion (ADME) pathways has been identified as the general mechanism for these changes, which can exacerbate the adverse drug reactions associated with these drugs (12) . The vast majority of altered ADME gene expression changes in NAFLD were observed after the progression to NASH, suggesting that NASH is where VDR will be most likely (16) . Previously, our group has shown that ex vivo activities of CYPs are altered in human NASH liver (17) .
Various experimental models have been established to mimic the pathological conditions of human NASH, although to date there is no single animal model that can accurately encompass the full spectrum of human NASH progression (18) . The leptin deficient ob/ob mice are widely used as a model of obesity, type II diabetes, and NAFLD, as they develop steatosis spontaneously (19, 20) . In addition, they exhibit metabolic signatures including insulin resistance, hyperinsulinemia, hyperglycemia and hyperlipidemia (21) . However, additional stimuli are required to drive the pathological development of NASH features, such as inflammation and fibrosis (22) . The methionine-and choline-deficient (MCD) diet, which disrupts the hepatic β-oxidation and the production of very low-density lipoprotein (VLDL) in animals, is widely employed to induce NASH in animal models (18, 23) . The ob/ob MCD model develops mRNA and protein expression profiles of hepatic transporters that are consistent with human NASH (24) , and was employed as a model for NASH in several mechanistic studies (15, 25, 26) . A 4-week MCD diet was fed to ob/ob mice to create our experimental diabetic NASH model.
In vivo analysis of CYP activity is the most accurate way to assess CYP function (27).
Administration of probe drugs in a cocktail approach is a preferable method to analyze in vivo activity of multiple CYP isoforms simultaneously (28). Probe drugs used in this study include caffeine, losartan, omeprazole, midazolam and dextromethorphan, which are the selective substrates of human CYP1A2, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 isoforms respectively. In the present study, we characterized the reported mouse orthologs, or highly potential counterparts of human CYP isoforms listed above: Cyp1a2, Cyp2c29, Cyp2d22 and Cyp3a11, in order to reflect NASH-associated changes in CYP activity in mouse models (29-32).
The purpose of the present study was to determine the in vivo alterations of the major CYP enzymatic activities in ob/ob and ob/ob MCD mouse models. By comparing these data to a previous ex vivo human study (17) , we determined whether this model can accurately replicate the CYP remodeling seen in human NASH. In Vivo pharmacokinetics of probe drugs:
Material and Methods

Chemicals
Mice were dosed by oral gavage with five-drug cocktail comprising caffeine (5mg/kg), losartan (40mg/kg), omeprazole (15mg/kg), dextromethorphan (20mg/kg) and midazolam (5mg/kg). In all cases, whole blood (30μL) was taken from the tail vein at intervals of drug postadministration (30, 60, 120, 240 and 360minutes), into a tube coated with heparin. Plasma samples were obtained by centrifugation.
Sample preparation and LC-MS/MS analysis:
The plasma samples (5μL) were spiked with an internal standard (10μL of 400 ng/mL RNA isolation and mRNA analysis:
Total RNA was extracted from liver tissues using RNAzol B reagent from Tel-Test Inc. Concordance analysis across human and ob/ob MCD mice:
Concordance analysis was performed to compare diabetic NASH mice to human NASH on the enzymatic activity, mRNA expression and protein expression of the CYP isoforms: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The analysis was conducted by measuring the effect size of NASH versus control, in the mice is the ob/ob MCD versus WT while in human is NASH with/without fatty versus normal, of either enzymatic activity, mRNA expression or protein expression. The effect size (estimated by Glass's D) is defined as the standardized mean difference between two populations and can be calculated using the following equation:
where μ1 and μ2 are the sample means for two groups, and Sp is the pooled standard deviation for both. Data of this study were compared to the published data in human (17) . The analysis was performed using R version 3. GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA).
Results
NASH phenotype in mouse models
Hematoxylin and eosin stained liver tissue sections from representative WT, ob/ob and ob/ob MCD mice are shown in Figure 1A . Livers were evaluated and incidence/severity scored by a board certified veterinary pathologist ( Figure 1B) . Macrovesicular steatosis, a distinguishing characteristic of NASH, was only observed in the ob/ob MCD mice. The ob/ob MCD exhibited greater incidence/severity scores on each of the typical NASH histological diagnoses, including hepatic steatosis, inflammation, fibrosis, biliary hyperplasia and hepatocyte necrosis compared to the WT ( Figure 1B ). To determine the diabetic phenotype, plasma glucose and insulin levels were examined in each group of mice. ob/ob mice displayed a diabetic phenotype with higher levels insulin. The glucose levels significantly decreased in ob/ob MCD mice, but a significant change of insulin level was not observed in ob/ob MCD mice ( Figure 1C ).
In vivo Pharmacokinetics of a Drug Cocktail in NASH models
A single dose oral pharmacokinetics study was performed using a cocktail of CYP probe drugs Figure 2A and Figure 2B , respectively, and the pharmacokinetic parameters are summarized in Table 1 . The maximum concentration (Cmax) and the area under curve (AUC) of caffeine in diabetic and diabetic NASH mice were significantly increased, although the drug half-life (t1/2) was not significantly changed in diabetic or diabetic NASH mice ( Table 1 ). The metabolism AUC ratio, defined as the ratio of metabolite AUC to parent drug AUC, of each probe drug was calculated to represent the respective enzymatic activity. The metabolism AUC ratio of caffeine and omeprazole were significantly decreased in diabetic and diabetic NASH mice compared to wild type mice. The metabolism AUC ratio of losartan was significantly decreased in the diabetic NASH mice compared to diabetic mice ( Figure 2C ).
3. Hepatic CYP mRNA expression alteration in diabetic NASH models
The hepatic mRNA expression of the major CYP isoforms, Cyp1a2, Cyp2c29, Cyp2d22 and
Cyp3a11 were normalized to mRNA expression of beta-Actin, and the fold changes were shown in Figure 3 . The Cyp1a2 mRNA expression level was significantly decreased in diabetic and diabetic NASH mice. The diabetic mice had a decreased mRNA level of Cyp2c29 compared to the wild type mice. Additionally, the mRNA level of Cyp2c29 was significantly decreased in the diabetic NASH mice compared to both the wild type and the diabetic mice. The mRNA level of Cyp3a11 was significantly increased in the diabetic mice compared to wild type.
Hepatic CYP protein content alteration in diabetic NASH models
Western blot analysis was performed to determine the relative protein content of the major CYPs in mice of each group ( Figure 4A ). The fold change of protein content of each CYP isoform, which is normalized to Erk protein content, was shown in Figure 4B . In the diabetic mice, the protein expression of Cyp1a2, Cyp2c29 and Cyp2d22 were significantly decreased. Furthermore, a significant decrease in protein content of Cyp1a2, Cyp2c29, Cyp2d22 and Cyp3a was observed in the diabetic NASH mice compared to the wild type mice. However, the only significant change in the diabetic NASH mice compared to the diabetic mice was the decreased Cyp2d22 protein content. in 10-week old db/db mice (37) . Lastly, a microarray study, intended to identify the general gene expression alterations in the ob/ob, db/db and HFD-fed C57BL/6J mice, revealed that the dramatically changed genes were highly interconnected and significantly enriched for processes involving metabolism by CYPs (38) . Collectively, these data indicate that, while there are similarities between mouse models of diabetes and NASH, they are not all the same and care
should be taken to understand the changes in CYP-mediated drug metabolism.
The concordance analysis between mouse in vivo and previously published human ex vivo data for CYP activity shows that even though the diabetic NASH mouse model we used in this study has been demonstrated to accurately reflect the drug transporter alteration profiles in humans, it partially recapitulates the alteration pattern of CYP1A2, CYP2C19 and CYP3A4, but fails to resemble the alterations of CYP2C9 and CYP2D6 observed in human NASH.
In conclusion, while the ob/ob MCD model accurately recapitulates certain aspects of human NASH including insulin insensitivity, pathological hallmarks, and transporter expression profiles, it cannot precisely reflect the alteration in the major CYP activities for drug metabolism. Studies modeling the effect of NASH on the disposition of drugs through the action of drug transporters may be highly relevant to human NASH patients, but caution should be used when extrapolating any CYP-mediated drug metabolism. More comprehensive human studies should be performed to evaluate the in vivo CYP activity in NASH patients. Additional effort should be devoted to 
